Abstract
The recent discovery of several molecules that negatively modulate the migration and growth of endothelial cells, collectively referred to as inhibitors of angiogenesis, has made it possible to test the hypothesis that control of angiogenesis might be an effective strategy in controlling tumor growth, as well as ameliorating the course of other lifethreatening diseases. Angiogenesis inhibitors are heterogeneous in origin and potency, and their growing list includes products of the proteolysis of larger molecules with a different function, such as angiostatin and endostatin, natural modulators of vascular endothelial growth factor activity, such as sFLT-1, and some cytokines with a marked antiendothelial activity, such as IL-12 and interferon-a. Pre-clinical studies have clearly indicated that most of these factors exert cytostatic rather than cytotoxic effects, thus implying the need for long-term administration in order to obtain a prolonged therapeutic effect. This feature of angiostatic therapy and the difficulty in synthesizing large amounts of recombinant functional proteins have prompted several studies, which have investigated their delivery by a gene therapy approach. This review addresses the several experimental approaches attempted to date, points out the constraints that have delayed clinical application, and envisions possible areas of integration between antiangiogenic gene therapy and other established therapeutic options against cancer.
Keywords: cancer gene therapy, angiogenesis, viral vector, interferon, endostatin
Current Gene Therapy
Title: Undermining Tumor Angiogenesis by Gene Therapy: An Emerging Field
Volume: 4 Issue: 3
Author(s): S. Indraccolo
Affiliation:
Keywords: cancer gene therapy, angiogenesis, viral vector, interferon, endostatin
Abstract: The recent discovery of several molecules that negatively modulate the migration and growth of endothelial cells, collectively referred to as inhibitors of angiogenesis, has made it possible to test the hypothesis that control of angiogenesis might be an effective strategy in controlling tumor growth, as well as ameliorating the course of other lifethreatening diseases. Angiogenesis inhibitors are heterogeneous in origin and potency, and their growing list includes products of the proteolysis of larger molecules with a different function, such as angiostatin and endostatin, natural modulators of vascular endothelial growth factor activity, such as sFLT-1, and some cytokines with a marked antiendothelial activity, such as IL-12 and interferon-a. Pre-clinical studies have clearly indicated that most of these factors exert cytostatic rather than cytotoxic effects, thus implying the need for long-term administration in order to obtain a prolonged therapeutic effect. This feature of angiostatic therapy and the difficulty in synthesizing large amounts of recombinant functional proteins have prompted several studies, which have investigated their delivery by a gene therapy approach. This review addresses the several experimental approaches attempted to date, points out the constraints that have delayed clinical application, and envisions possible areas of integration between antiangiogenic gene therapy and other established therapeutic options against cancer.
Export Options
About this article
Cite this article as:
Indraccolo S., Undermining Tumor Angiogenesis by Gene Therapy: An Emerging Field, Current Gene Therapy 2004; 4 (3) . https://dx.doi.org/10.2174/1566523043346363
DOI https://dx.doi.org/10.2174/1566523043346363 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neurodegenerative Diseases and Flavonoids: Special Reference to Kaempferol
CNS & Neurological Disorders - Drug Targets MicroRNAs in Cancer Stem Cells: New Regulators of Stemness
Current Pharmaceutical Design Genetic Predisposition to Neonatal Tumors
Current Pediatric Reviews The Relevance of Supplemental Vitamin D in Malignancies
Anti-Cancer Agents in Medicinal Chemistry Acetylcholinesterase Inhibitors and Drugs Acting on Muscarinic Receptors- Potential Crosstalk of Cholinergic Mechanisms During Pharmacological Treatment
Current Neuropharmacology A Novel Platinum-based Compound with Preferential Cytotoxic Activity against a Panel of Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Cdc20: A Potential Novel Therapeutic Target for Cancer Treatment
Current Pharmaceutical Design TRPV1 Antagonists as a Potential Treatment for Hyperalgesia
Recent Patents on CNS Drug Discovery (Discontinued) Gadd45 Proteins as Critical Signal Transducers Linking NF-κB to MAPK Cascades
Current Cancer Drug Targets Cu-mediated synthesis of 2,3-dihydro-1H-pyrrolo[3,2,1-ij]quinolin-1-ones as potential inhibitors of sirtuins
Letters in Drug Design & Discovery Synthesis and Applications of Nanoflowers
Recent Patents on Nanotechnology Oxidative Stress and Antioxidants in Neurological Diseases: Is There Still Hope?
Current Drug Targets Is Fibroblast Growth Factor Receptor 4 a Suitable Target of Cancer Therapy?
Current Pharmaceutical Design Schistosoma mansoni Changes the Activity of Phase II Drug-Metabolizing Enzymes: Role of Praziquantel as Antibilharzial Drug
Drug Metabolism Letters A Facile and Green Synthesis of Novel Imide and Amidic Acid Derivatives of Phenacetin as Potential Analgesic and Anti-Pyretic Agents
Letters in Organic Chemistry Factors Modulating Fibrates Response: Therapeutic Implications and Alternative Strategies
Endocrine, Metabolic & Immune Disorders - Drug Targets UDP-Glucuronosyltransferases
Current Drug Metabolism The Use of Biomarkers for Bladder Cancer Diagnosis and Surveillance
Mini-Reviews in Medicinal Chemistry Free Radical Attack on Cholesterol: Oxysterols as Markers of Oxidative Stress and as Bioactive Molecules
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Concentrations of Cd, Cu, Pb and Zn in Blood Serum of Cancer Patients and Comparison with Healthy Person by Atomic Absorption Spectrometry
Current Analytical Chemistry